{"nctId":"NCT02079246","briefTitle":"Long-term Safety and Tolerability of Idalopirdine (Lu AE58054) as Adjunctive Treatment to Donepezil in Patients With Mild-moderate Alzheimer's Disease","startDateStruct":{"date":"2014-04-07","type":"ACTUAL"},"conditions":["Alzheimer's Disease"],"count":1463,"armGroups":[{"label":"Idalopirdine (Lu AE58054) 60 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Idalopirdine 60 mg"]},{"label":"Idalopirdine 60 mg + memantine","type":"EXPERIMENTAL","interventionNames":["Drug: Idalopirdine 60 mg"]}],"interventions":[{"name":"Idalopirdine 60 mg","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* the patient has completed Visit 7 (Completion Visit) in the lead-in double-blind, placebo controlled clinical studies 14861A/NCT01955161 or 14862A/NCT02006641\n\nFor patients in the OLEX-MEM:\n\n* The patient has completed Visit 6 (Week 28) of the OLEX.\n* The patient, according to the judgement of the investigator, requires initiation of treatment with memantine as per local label/SmPC/treatment guidelines.\n\nExclusion Criteria:\n\n* The patient has a moderate or severe ongoing adverse event from the lead-in study considered a potential safety risk by the investigator.\n* The patient has experienced seizures before Completion Visit in the lead-in study.\n* The patient has evidence of clinically significant disease.\n* The patient's donepezil treatment is likely to be interrupted or discontinued during the study.\n* The patient is receiving therapy with another acetylcholinesterase inhibitors (AChEI).\n\nOther protocol-defined inclusion and exclusion criteria may apply.","healthyVolunteers":false,"sex":"ALL","minimumAge":"50 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Treatment Emergent Adverse Events (TEAEs) in the OLEX","description":"A TEAE is an adverse event that starts or increases in intensity after the date of Baseline II.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2130","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of TEAEs in the OLEX-MEM","description":"A TEAE is an adverse event that starts or increases in intensity after the date of Baseline III (start of OLEX-MEM).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"93","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Cognition","description":"Change from Baseline II to Week 28 in Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-Cog) total score. The ADAS-cog is a 11-item neuropsychological test that assess the severity of cognitive impairment. The items determine the patient's orientation, memory, language, and praxis. Total score of the 11 items range from 0 to 70 (lower score indicates lower cognitive impairment).","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.01","spread":"0.22"},{"groupId":"OG001","value":"2.67","spread":"0.23"}]}]}]},{"type":"SECONDARY","title":"Clinical Global Impression Score","description":"Alzheimer's Disease Cooperative Study - Clinical Global Impression of Change (ADCS-CGIC) score at Week 28. The ADCS-CGIC is a semi-structured interview to assess clinically relevant changes in patients with AD. The items determine cognition, behavior, social and daily functioning. Severity at baseline is rated on a 7-point scale from 1 (normal, not ill at all) to 7 (among the most extremely ill patients). The clinically relevant change from baseline is rated on a 7-point scale from 1 (marked improvement) to 7 (marked worsening).","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.58","spread":"0.005"},{"groupId":"OG001","value":"4.61","spread":"0.05"}]}]}]},{"type":"SECONDARY","title":"Change in Daily Functioning","description":"Change from Baseline II to Week 28 in Alzheimer's Disease Cooperative Study - Activities of Daily Living Inventory (ADCS-ADL23) total score. The ADCS-ADL23 is a 23-item clinician-rated inventory to assess activities of daily living (conducted with a caregiver or informant). Each item comprises a series of hierarchical sub-questions, ranging from the highest level of independent performance to a complete loss for each activity. Total score of the 23 items ranges from 0 to 78 (higher score indicates lower disability).","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.71","spread":"0.28"},{"groupId":"OG001","value":"-3.88","spread":"0.32"}]}]}]},{"type":"SECONDARY","title":"Change in Behavioural Disturbance","description":"Change from Baseline II to Week 28 in Neuropsychiatric Inventory (NPI) total score. The NPI is a 12-item structured interview with a caregiver to assess behavioural disturbances. The NPI comprises 10 behavioural and 2 neurovegetative items. Each item consists of a screening question and several sub-questions that are rated no (not present) or yes (present). Each item is rated for frequency (a 4-point scale from 1 \\[occasionally\\] to 4 \\[very frequent\\]) and severity (a 3-point scale from 1 \\[mild\\] to 3 \\[marked\\]). The total NPI score is the frequency ratings multiplied by the severity ratings and ranges from 0 to 144 (higher score indicates worse outcome).","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.80","spread":"0.35"},{"groupId":"OG001","value":"1.36","spread":"0.34"}]}]}]},{"type":"SECONDARY","title":"Change in Cognitive Aspects of Mental Function","description":"Change from Baseline II to Week 28 in Mini Mental State Examination (MMSE). The MMSE is an 11-item test to assess the cognitive aspects of mental function. The subtests assess orientation, memory, attention, language, and visual construction. The scores for each item is dichotomous (1 = response is correct, 0 = response is incorrect). Total score of the 11 items ranges from 0 to 30 (higher score indicates lower deficit).","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.28","spread":"0.10"},{"groupId":"OG001","value":"-1.02","spread":"0.11"}]}]}]},{"type":"SECONDARY","title":"Change in Cognitive Aspects of Mental Function","description":"Change from Baseline III to Week 52 in Mini Mental State Examination (MMSE). The MMSE is an 11-item test to assess the cognitive aspects of mental function. The subtests assess orientation, memory, attention, language, and visual construction. The scores for each item is dichotomous (1 = response is correct, 0 = response is incorrect). Total score of the 11 items ranges from 0 to 30 (higher score indicates lower deficit).","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.55","spread":"0.26"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":91,"n":1462},"commonTop":["Accidental overdose","Fall"]}}}